<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-920-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEMPLAR 5 mcg/ml solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PARICALCITOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µ/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        266.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Avara Liscate Pharmaceutical services S.p.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Avara Liscate Pharmaceutical services S.p.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbvie Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A11CC07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zemplar contains the active substance paricalcitol, which is a synthetic form of active vitamin D.</p><p>&nbsp;</p><p>Active vitamin D is required for the normal functioning of many tissues in the body, including the parathyroid gland and bones. In people who have normal kidney function, this active form of vitamin D is naturally produced by the kidneys, but in kidney failure the production of active vitamin D is markedly reduced. Zemplar therefore provides a source of active vitamin D, when the body cannot produce enough and helps to prevent the consequences of low levels of active vitamin D, in patients with chronic kidney disease namely high levels of parathyroid hormone which can cause bone problems. Zemplar is used in adult patients with kidney disease Stages 5.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Zemplar</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to paricalcitol or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have very high levels of calcium or vitamin D in your blood.&nbsp;</p><p>Your doctor will be able to tell you if these conditions apply to you.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before being given Zemplar.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; before the treatment begins, it is important to limit the amount of phosphorus in your diet. Examples of foods high in phosphorous include tea, soda, beer, cheese, milk, cream, fish, chicken or beef liver, beans, peas, cereals, nuts, and grains.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phosphate-binding medicines, which keep phosphate from being absorbed from your food, may be needed to control phosphorus levels.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking calcium-based phosphate binders, the doctor may need to adjust your dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor will need to do blood tests to monitor your treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Zemplar</strong></p><p>Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines may affect the action of this medicine or may increase the likelihood of side effects.&nbsp; It is particularly important to tell your doctor if you are taking any of the following medicines:</p><ul><li>to treat fungal infections such as candida or thrush, (for example ketoconazole)</li><li>to treat heart problems or high blood pressure (for example digoxin, diuretics or water pills).&nbsp;</li><li>that contain a source of phosphate (for example, medicines to lower calcium levels in the blood)</li><li>that contain calcium or vitamin D, including supplements and multivitamins that can be bought without a prescription</li><li>that contain magnesium or aluminium, for example some types of indigestion medicines (antacids) and phosphate-binders</li><li>to treat elevated cholesterol levels (for example cholestyramine)</li></ul><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>It is not known if it is safe for pregnant women to use this medicine, therefore its use is not recommended during pregnancy or if you may become pregnant.</p><p>It is not known if paricalcitol passes into human breast milk. Tell your doctor before breast-feeding while taking Zemplar.</p><p>&nbsp;</p><p><strong>Driving and using machines&nbsp;</strong></p><p>Zemplar may make you feel dizzy, which can affect your ability to drive safely or use heavy machines.</p><p>Do not drive or use machines if you feel dizzy.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Zemplar contains ethanol&nbsp;</strong></p><p>This medicinal product contains 20% v/v of ethanol (alcohol). Each dose may contain up to 1.3g ethanol which may be harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high risk groups such as patients with liver disease or epilepsy.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will use the results of your laboratory tests to decide the correct starting dose for you. Once treatment with Zemplar has started, the dose may be adjusted, based upon the results of routine laboratory tests.&nbsp; Using your lab results, your doctor will help determine the correct dose of Zemplar for you.</p><p>Zemplar will be given by a doctor or nurse while you are having your treatment on the kidney machine. It will be given through the tube (bloodline) that is used to connect you to the machine. You will not need to have an injection because Zemplar can be put directly into the tube that is being used for your treatment. You will not be given Zemplar more frequently than every other day and not more than three times a week.</p><p>&nbsp;</p><p><strong>If you are given too much<em> </em>Zemplar</strong></p><p>Too much Zemplar can cause abnormally high levels of calcium in the blood, which can be harmful.&nbsp; Symptoms which can appear soon after taking too much Zemplar may include a feeling of weakness and/or drowsiness, headache, nausea (feeling sick) or vomiting (being sick), a dry mouth, constipation, pains in muscles or bones and a metallic taste in the mouth.</p><p>If you experience high level of calcium in your blood after taking Zemplar, your doctor will ensure you receive the appropriate treatment to return your calcium to normal limits. Once your calcium levels return to normal limits, you may be given Zemplar at a lower dose.</p><p>&nbsp;</p><p>Your doctor will be checking your blood levels. If you experience any of the above, seek medical advice immediately.</p><p>Symptoms which can develop over a longer period of receiving too much Zemplar include loss of appetite, drowsiness, weight loss, sore eyes, a runny nose, itchy skin, feeling hot and feverish, loss of sex drive and severe abdominal pain (due to an inflamed pancreas) and kidney stones.&nbsp; Your blood pressure may be affected and heart beat irregularities (palpitations) can occur.&nbsp; The results of blood and urine tests may show high cholesterol, urea, nitrogen and raised levels of liver enzymes. Zemplar may rarely cause mental changes including confusion, drowsiness, insomnia or nervousness.</p><p>Zemplar contains 30% by volume of Propylene glycol as an ingredient. Cases of poisonous effects related to the high doses of Propylene glycol have only rarely been reported and would not be expected when being given to kidney patients on a kidney machine because Propylene glycol is removed from the blood during dialysis.</p><p>If you receive too much Zemplar, or experience any of the above, seek medical advice immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Various allergic reactions have been seen with Zemplar. <strong>Important: Tell your doctor or nurse immediately if you notice any of the following side effects: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing or swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wheezing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itchy skin, or including hives</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, mouth, tongue or throat.</p><p>&nbsp;</p><p>Tell your doctor or nurse if you notice any of the following side effects:</p><p>&nbsp;</p><p><strong><u>Common (may affect up to 1 in 10 people) are:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of parathyroid hormone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of calcium (feeling sick or being sick, constipated or confused); phosphorous in the blood (probably no symptoms but it can make bones more likely to break)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual taste in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy skin</p><p>&nbsp;</p><p><strong><u>Uncommon (may affect up to 1 in 100 people) are:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood infection, pneumonia (lung infection), sore throat, infections in the vagina, influenza</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of red cells (anaemia &ndash; feeling weak, shortness of breath, looking pale); decreased number of white cells (more likely to get infections); swollen glands in the neck, armpit and/or groin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of parathyroid hormones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of potassium in the blood, low levels of calcium in the blood, loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, which is sometimes severe (delirium), personality disorders (not feeling like yourself), agitation (feeling jittery, anxious), problems sleeping, nervousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coma (a deep state of unconsciousness during which the person cannot respond to the environment), stroke, fainting, muscular spasms in arms and legs, even during sleep, decreased touch sensation, tingling or numbness, dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased pressure in the eye, pink eye (itchy/crusty eyelids)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; earache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack, irregular/fast heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid on the lungs, asthma, wheezing, difficulty breathing, nose bleeds, cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the rectum, inflammation of the colon, diarrhoea, stomach ache, difficulty swallowing, constipation, nausea, vomiting, dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash with itchy blisters, hair loss, excessive hair growth, excessive and unpredictable sweats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain, joint stiffness, back pain, muscle twitching, muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast pain, difficulty having an erection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal way of walking, general swelling or localised swelling of the ankles, feet and legs, injection site pain, fever, chest pain, unusual tiredness or weakness, a general feeling of discomfort, thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased bleeding time (blood will not clot so quickly), increase of a liver enzyme, change in laboratory test results, weight loss</p><p>&nbsp;</p><p><strong><u>Not known Frequency </u></strong><u>(frequency cannot be estimated from the available data)</u><strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing; itchy skin (hives); stomach bleeding.&nbsp;</p><p>&nbsp;</p><p>You may not be able to tell if you have some of the side effects listed above unless you are told so by your doctor.</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist immediately.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below).</p><p><strong>To report any side effect(s):</strong></p><ul><li><em>Saudi Arabia:</em></li></ul><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><ul><li><em>Other GCC States:</em></li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>By reporting side affects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30˚C.</p><p>Zemplar should be used immediately after opening.</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP.&nbsp; The expiry date refers to the last date of that month.</p><p>Do not use this medicine if you notice particles or discolouration.</p><p>Do not throw away any medicines via wastewater or household waste. &nbsp;Ask your pharmacist how to throw away&nbsp; medicines you no longer use.&nbsp; These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zemplar contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is paricalcitol. Each ml of solution contains 5 micrograms of paricalcitol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: ethanol (alcohol), propylene glycol, and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zemplar solution for injection is a watery, clear and colorless solution, free from visible particles.

It is supplied in containers with 5 glass ampules of 1 ml or 2 ml or 5 glass vials of 1 ml or 2 ml.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>AbbVie Ltd,</p><p>Maidenhead,</p><p>SL6 4UB, United Kingdom</p><p>&nbsp;</p><p><strong>Vial Manufacturer:</strong></p><p>Avara Liscate Pharmaceutical services S.p.A. Via Fosse Ardeatine, Liscate (MI), Italy</p><p>AbbVie S.r.l, S.R. Campoverde di Aprilia (LT), Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زمبلار على المادة الفعالة باريكالسيتول، وهي شكل تركيبي من الفيتامين د النشط.&nbsp;&nbsp;&nbsp;</p><p>فيتامين د النشط ضروري من أجل الأداء الوظيفي الطبيعي للعديد من أنسجة الجسم، بما في ذلك الغدة الدريقية والعظام. عند الأفراد الذين يتمتعون بوظيفة كلوية طبيعية، تنتج الكليتان هذا الشكل النشط من الفيتامين د بشكل طبيعي، ولكن في حالات الفشل الكلوي، فإن إنتاج الفيتامين د النشط يتراجع بشكل واضح. لذا يوفّر زمبلار مصدرا لفيتامين د النشط، عندما لا يتمكن الجسم من إنتاج ما يكفي منه ويساعد على الوقاية من عواقب المستويات المنخفضة من فيتامين د النشط، لدى المرضى المصابين بمرض كلوي مزمن أي ارتفاع معدّلات هرمون الدُّرَيْقات الذي قد يسبب مشاكل في العظام. يستعمل زمبلار لدى المرضى البالغين المصابين بالمرحلة الخامسة من المرض الكلوي المزمن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب أن لا تُعطى زمبلار </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالحساسية تجاه باريكالسيتول أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بارتفاع معدّل الكالسيوم أو الفيتامين د في دمك.&nbsp;</p><p>&nbsp;</p><p dir="RTL">سيتمكن طبيبك من إخبارك إذا كانت هذه الحالات تنطبق عليك.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الممرضة قبل أن تُعطى زمبلار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل البدء بالعلاج، من المهم أن تحدّد كمية الفُسفور في حميتك الغذائية. تشمل الأمثلة عن الأغذية التي تحتوي على الفُسفور الشاي، الصودا، البيرة، الأجبان، الحليب، الكريم (القشد، السمك، كبد الدجاج أو البقر، الفول، البازلاء، الحبوب، المكسرات، والبقول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحتاج لاستعمال الأدوية الرابطة للفُسفات، التي تمنع امتصاص الفُسفات من الطعام الذي تتناوله، من أجل التحكم بمعدلات الفُسفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول رابطات الفُسفات الكلسية الأساس، فقد يحتاج الطبيب إلى تعديل جرعتك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيحتاج الطبيب لإجراء اختبارات الدم لمراقبة علاجك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وزمبلار</strong></p><p dir="RTL">أعلم طبيبك، الممرضة أو الصيدلاني إذا كنت تتناول حالياً، تناولت مؤخّراً، أو قد تتناول أي دواء آخر.&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد تؤثر بعض الأدوية على عمل هذا الدواء أو قد تؤدي إلى زيادة إمكانية حدوث التأثيرات الجانبية. من المهم بشكل خاص أن تخبر طبيبك إذا كنت تتناول أيا من الادوية التالية:&nbsp;</p><ul><li dir="RTL">الأدوية التي تستعمل لعلاج حالات العدوى الفطرية مثل داء المبيضات أو السلاق، (مثل كيتوكونازول على سبيل المثال)</li><li dir="RTL">الأدوية التي تستعمل لعلاج اضطرابات القلب أو ارتفاع ضغط الدم (مثل الديجوكسين، الأدوية المدرّة أو أقراص الماء)&nbsp;</li><li dir="RTL">الأدوية التي تحتوي على مصدر للفُسفات (مثل الأدوية التي تخفض معدلات الكالسيوم في الدم)</li><li dir="RTL">الأدوية التي تحتوي على الكالسيوم أو الفيتامين د، بما في ذلك المكملات ومركبات الفيتامينات المتعددة التي يمكن شراؤها دون وصفة طبية</li><li dir="RTL">الأدوية التي تحتوي على المغنيزيوم أو الألمنيوم، مثل بعض أنواع أدوية عسر الهضم (مضادات الحموضة) ورابطات الفُسفات</li><li dir="RTL">الأدوية التي تستعمل لعلاج معدلات الكولسترول المرتفعة (مثل الكوليستيرامين)</li></ul><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع </strong></p><p dir="RTL">إذا كنت حاملا أو مرضعا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، فاطلبي نصيحة طبيبك قبل تلقي هذا الدواء.</p><p dir="RTL">ليس من المعروف ما إذا كان استعمال هذا الدواء آمنا بالنسبة للنساء الحوامل، لذا لا يوصى باستعماله في اثناء الحمل أو إذا كنت ستصبحين حاملا.</p><p dir="RTL">ليس من المعروف ما إذا كان باريكالسيتول ينتقل إلى حليب الثدي. أخبري طبيبك قبل الإرضاع إذا كنت تتلقين زمبلار.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآليات</strong></p><p dir="RTL">قد يجعلك زمبلار تشعر بالدوخة، مما قد يؤثر على قدرتك على القيادة بأمان أو استعمال الآليات الثقيلة.</p><p>&nbsp;</p><p dir="RTL">امتنع عن القيادة أو استعمال الآليات إذا كنت تشعر بالدوخة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>يحتوي زمبلار على الإيثانول</strong></p><p dir="RTL">يحتوي هذا المستحضر الدوائي على ٢٠٪ ح/ح من الإيثانول (كحول). قد تحتوي كل جرعة على ما يصل إلى ١٫٣ غرام من الإيثانول الذي قد يكون مؤذيا للذين يعانون من الكحولية (إدمان الكحول). يجب وضع هذا الأمر في الاعتبار لدى السيدات الحوامل والمرضعات، الأطفال ومجموعات المرضى مرتفعة الخطورة مثل المرضى المصابين بمرض كبدي أو بالصرع.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعتمد طبيبك على نتائج فحوصاتك المخبرية ليقرر الجرعة الابتدائية الصحيحة المناسبة لك. بمجرد أن يبدأ علاجك بواسطة زمبلار، من الممكن أن يتم تعديل الجرعة، استنادا إلى نتائج الفحوصات المخبرية الدورية. بالاعتماد على نتائج فحوصاتك المخبرية، سيقرر طبيبك جرعة زمبلار الصحيحة المناسبة لك.</p><p>&nbsp;</p><p dir="RTL">سيُعطى زمبلار من قبل طبيب أو ممرضة أثناء تلقيك لعلاجك على جهاز الكلى. وسيُعطى عن طريق الأنبوب (خط الدم) المستعمل لوصلك بالجهاز. لن تكون بحاجة لتلقي حقنة لأن زمبلار يمكن وضعه مباشرة في الأنبوب المستعمل لعلاجك. لن تُعطى زمبلار بمعدل أكثر من مرة كل يومين وبما لا يتجاوز ثلاث مرات أسبوعيا.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أعطيت كمية كبيرة جدا من زمبلار</strong></p><p dir="RTL">قد تسبب الكميات الكبيرة من زمبلار معدلات مرتفعة جدا من الكالسيوم في الدم، وهذا ما قد يكون مؤذيا. من الممكن أن تتضمن الأعراض التي قد تظهر سريعا بعد تلقي كميات كبيرة جدا من زمبلار الشعور بالضعف و / أو الدوخة، الصداع، الغثيان (الشعور بحاجة للتقيؤ) أو التقيؤ، الفم الجافّ، الإمساك، آلام عضلية أو عظمية والشعور بطعم معدني في الفم.</p><p dir="RTL">إذا أصبت بارتفاع معدل الكالسيوم في الدم بعد تلقي زمبلار، سيحرص طبيبك على أن تتلقى العلاج المناسب لإعادة الكالسيوم لديك إلى حدوده الطبيعية. بمجرد أن تعود معدلات الكالسيوم لديك إلى حدودها الطبيعية، من الممكن أن تعطى زمبلار بجرعة أقلّ.</p><p dir="RTL">سيلجأ طبيبك ايضا لإجراء فحوص للدم ليتأكد من معدل الكالسيوم في دمك. إذا عانيت من أي مما ذكر أعلاه، فاطلب مشورة طبية على الفور.</p><p>&nbsp;</p><p dir="RTL">تتضمن الأعراض التي قد تظهر بعد فترة أطول من تلقي كميات كبيرة جدا من زمبلار نقص الشهية، الدوخة، نقص الوزن، ألم العينين، سيلان الأنف، جلد حاكّ، الشعور بالدفء وارتفاع الحرارة، فقد الرغبة الجنسية وألم شديد في البطن (نتيجة لالتهاب البنكرياس) والحصيات الكلوية. قد يتأثر ضغط الدم لديك ومن الممكن أن تحدث اضطرابات في ضربات القلب (خفقان). قد تُظهر نتائج الفحوصات على الدم والبول ارتفاع الكولسترول، البولة، النتروجين ومعدلات مرتفعة للخمائر الكبدية. في حالات نادرة قد يسبب زمبلار تغيرات ذهنية تتضمن الارتباك، النعاس، الأرق أو العصبية.</p><p>&nbsp;</p><p dir="RTL">يحتوي زمبلار على ٣٠٪ من حجمه من بروبلين الغليكول كأحد المكونات. ذكر حدوث حالات التأثيرات السمية ذات الصلة ببروبلين الغليكول في حالات نادرة فقط، وهي غير متوقعة الحدوث عند إعطائه لمرضى الكلية الموضوعين على جهاز الكلى لأن بروبلين الغليكول يزاح من الدم أثناء عملية الديال.</p><p>&nbsp;</p><p dir="RTL">إذا تلقّيت كمية كبيرة جدا من زمبلار، أو عانيت من أي مما ذكر أعلاه، فاطلب مشورة طبية على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p>&nbsp;</p><p dir="RTL">لوحظ حدوث تفاعلات تحسسية متنوعة مع زمبلار. <strong>هام: أخبر طبيبك على الفور إذا لاحظت حدوث أي من التأثيرات الجانبية التالية: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس أو البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صفير الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح، جلد حاكّ، أو به شرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، اللسان أو الحلق.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة إذا لاحظت حدوث أي من التأثيرات الجانبية التالية:</p><p><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>شائعة (قد تصيب حتى ١ من ١٠ أشخاص) وهي:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدلات منخفضة من هرمون الدُّريقات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدلات مرتفعة من الكالسيوم (الشعور بالغثيان أو التقيؤ، الإمساك أو الارتباك)؛ ازدياد معدل الفّسفور في الدم (من المحتمل ألا يترافق بأعراض ولكنه يجعل العظام أكثر قابلية للإصابة بالكسور)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طعم غير اعتيادي في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلد حاكّ</p><p>&nbsp;</p><p dir="RTL"><strong><u>غير شائعة (قد تصيب حتى ١ من ١٠٠ شخص) وهي:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الدم، ذات الرئة (عدوى الرئة)، ألم الحلق، حالات العدوى في المهبل، الانفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص عدد خلايا الدم الحمراء (فقر الدم - الشعور بالضعف، ضيق النفس، المظهر الشاحب)؛ تناقص عدد خلايا الدم البيضاء (أرجحية الإصابة بحالات العدوى)؛ غدد متورمة في العنق، الإبط و/أو المغبن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدلات مرتفعة من هرمون الدُّريْقات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدلات مرتفعة من البوتاسيوم في الدم، معدلات منخفضة من الكالسيوم في الدم، فقد الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك، قد يكون شديدا في بعض الأحيان (هذيان)، اضطرابات شخصية (الشعور بأنك لست أنت)، هياج (الشعور بالعصبية، القلق)، مشاكل في النوم، العصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غيبوبة (حالة عميقة من الغياب عن الوعي لا يتمكن المرء في أثنائها من التجاوب مع محيطه)، سكتة دماغية، إغماء، تشنجات عضلية في الذراعين والساقين، حتى أثناء النوم، تناقص حسّ اللمس، نخز أو تنميل، دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط العين، العين الوردية (جفون حاكة / متقشرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الأذن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية، ضربات قلب سريعة / غير منتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع سائل على الرئة، ربو، صفير الصدر، صعوبة التنفس، نزف من الأنف، سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف من المستقيم، التهاب القولون، إسهال، ألم المعدة، صعوبة البلع، إمساك، غثيان، تقيؤ، جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع نفاطات حاكّة، سقوط الشعر، نمو الشعر المفرط، تعرق مفرط وغير متوقّع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل، تيبّس المفاصل، ألم الظهر، نفضان عضلي، ألم عضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الثدي، صعوبة الحصول على انتصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشي بطريقة غير طبيعية، تورم عامّ أو موضعي في الكاحلين، القدمين والساقين، ألم في موضع الحقن، حمى، ألم الصدر، تعب أو ضعف غير اعتيادي، شعور عام بالإزعاج، عطش&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تطاول زمن النزف (لن يتخثر الدم بسرعة)، زيادة الخمائر الكبدية، تغيرات في نتائج الفحوص المخبرية، نقص الوزن</p><p>&nbsp;</p><p dir="RTL"><strong><u>ذات معدّل حدوث غير معروف</u></strong><u> (لا يمكن تقدير معدل الحدوث من البيانات المتوفرة):</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الوجه، الشفتين، الفم، اللسان أو الحلق الذي قد يؤدي إلى صعوبة في البلع أو التنفس؛ جلد حاك (شرى)؛ نزف المعدة.&nbsp;</p><p dir="RTL">قد لا تتمكن من معرفة ما إذا كنت مصابا ببعض التأثيرات الجانبية المشار إليها أعلاه إلا إذا كان طبيبك قد أخبرك بذلك.</p><p dir="RTL">إذا ازدادت شدة أي من التأثيرات الجانبية، أو لاحظت ظهور أي تأثيرات جانبية غير مذكورة في هذه النشرة، الرجاء إبلاغ طبيبك، الممرضة أو الصيدلاني على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أصبت بأي تأثير جانبي، تحدّث إلى طبيبك أو الصيدلاني. وهذا يشمل أي تأثيرات جانبية غير مدرجة في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة (انظر التفاصيل أدناه).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي تأثير(ات) جانبي(ـة):</strong></p><ul><li dir="RTL"><em>المملكة العربية السعودية</em>:</li></ul><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية&nbsp;</p><p dir="RTL">اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على هاتف: +966-11-2038222 تحويلة: 2317 &ndash; 2356 &ndash; 2353 - 2354 -&nbsp; 2334 - 2340.</p><p dir="RTL">فاكس: +966-11-205-7662</p><p dir="RTL">الهاتف المجاني:&nbsp; 8002490000</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني:&nbsp; www.sfda.gov.sa/npc</p><ul><li dir="RTL"><em>بلدان مجلس التعاون الخليجي الأخرى</em>:</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالجهات المختصة المسؤولة.</p><p>&nbsp;</p><p dir="RTL">بالإبلاغ عن التأثيرات الجانبية يمكنك أيضا المساعدة بتوفير مزيد من المعلومات عن سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحتفظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم.</p><p dir="RTL">احفظه في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">يجب أن يستعمل زمبلار مباشرة بعد الفتح.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المبيّن على الكرتونة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المشار إليه.</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظت وجود جسيمات أو تغيرا في لونه.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه المجاري العامة أو مع قمامة المنزل. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات تساعد على حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي باريكالسيتول. كل ١ مل من المحلول يحتوي على ٥ مكغم من باريكالسيتول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: إيثانول (كحول)، بروبلين الغليكول، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو زمبلار ومحتويات العبوة</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">محلول زمبلار للحقن هو محلول مائي صافٍ وعديم اللون، خال من الجسيمات المرئية.&nbsp;</p><p dir="RTL">يتوفر في حاويات تحتوي على ٥ أمبولات زجاجية سعة ١ مل أو ٢ مل أو ٥ قناني زجاجية سعة ١ مل أو ٢ مل.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق:</strong></p><p dir="RTL">آبفي ليمتد،</p><p dir="RTL">ميدنهيد</p><p dir="RTL">المملكة المتحدة</p><p>AbbVie Ltd,</p><p>Maidenhead,</p><p>SL6 4UB,</p><p>United Kingdom</p><p>&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong><strong> </strong></p><p dir="RTL">Avara Liscate Pharmaceutical services S.p.A. Italy</p><p dir="RTL">أفارا ليسكيت للخدمات الصيدلانية إس بي إي، ، ليسكيت (إم آي)، إيطاليا</p><p>AbbVie S.r.l, Italy</p><p dir="RTL">آبفي إس آر إل، إس آر كامبو فيردي دي أبريليا (إل تي)، إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في نيسان (أبريل) ٢٠١٨ 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zemplar 5 micrograms/ml solution for injection 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of solution for injection contains 5 micrograms of paricalcitol. 

Each 1 ml ampoule contains 5 micrograms of paricalcitol.

Each 1 ml vial contains 5 micrograms of paricalcitol.

Excipients: Ethanol (20% v/v) and propylene glycol (30% v/v)
For a full list of excipients see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection
A clear and colourless aqueous solution free from visible particles

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paricalcitol is indicated in adults for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure who are undergoing haemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology </u></p><p><u>Adults</u></p><p>1)&nbsp; <u>Initial Dose should be calculated based on baseline parathryroid hormone (PTH) levels:</u></p><p>&nbsp;</p><p>The initial dose of paricalcitol is based on the following formula:</p><p>&nbsp;</p><p>Initial dose (micrograms) = <u>baseline intact PTH level in pmol/l </u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OR</p><p>&nbsp;</p><p>= <u>baseline intact PTH level in pg/mL </u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 80</p><p>&nbsp;</p><p>and administered as an intravenous (IV) bolus dose no more frequently then every other day at any time during dialysis.</p><p>The maximum dose safely administered in clinical studies was as high as 40 micrograms.</p><p>&nbsp;</p><p>2)&nbsp; <u>Titration Dose:</u></p><p>The currently accepted target range for PTH levels in end-stage renal failure subjects undergoing dialysis is no more than 1.5 to 3 times the non-uremic upper limit of normal, 15.9 to 31.8 pmol/l (150-300 pg/ml), for intact PTH. Close monitoring and individual dose titration are necessary to reach appropriate physiological endpoints.&nbsp; If hypercalcaemia or a persistently elevated corrected Ca x P product greater than 5.2 mmol<sup>2</sup>/l<sup>2</sup> (65 mg<sup>2</sup>/dl<sup>2</sup>) is noted, the dosage should be reduced or interrupted until these parameters are normalised. Then, paricalcitol administration should be reinitiated at a lower dose. Doses may need to be decreased as the PTH levels decrease in response to therapy.</p><p>&nbsp;</p><p>The following table is a suggested approach for dose titration:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Suggested Dosing Guidelines</strong></p><p><strong>(Dose adjustments at 2 to 4 week intervals)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>iPTH Level Relative to Baseline</strong></p></td><td style="vertical-align:top"><p><strong>Paricalcitol Dose Adjustment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Same or increased</p></td><td rowspan="2"><p>Increase by 2 to 4 micrograms</p></td></tr><tr><td style="vertical-align:top"><p>Decreased by &lt;&nbsp;30%</p></td></tr><tr><td style="vertical-align:top"><p>Decreased by &sup3; 30%, <strong>&le;</strong> 60%</p></td><td style="vertical-align:top"><p>Maintain</p></td></tr><tr><td style="vertical-align:top"><p>Decreased &gt;&nbsp;60%</p></td><td rowspan="2"><p>Decrease by 2 to 4 micrograms</p></td></tr><tr><td style="vertical-align:top"><p>IPTH &lt;&nbsp;15.9 pmol/l (150 pg/mL)</p></td></tr></tbody></table><p>&nbsp;</p><p>Once dosage has been established, serum calcium and phosphate should be measured at least monthly. Serum intact PTH measurements are recommended every three months.&nbsp; During dose adjustment with paricalcitol, laboratory tests may be required more frequently.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Unbound concentrations of paricalcitol in patients with mild to moderate hepatic impairment are similar to healthy subjects and dose adjustment is not necessary in this patient population. There is no experience in patients with severe hepatic impairment.</p><p><u>Paediatric population (0-18 years)</u></p><p>The safety and efficacy of Zemplar in children have not been established.&nbsp; No data are available on children under 5 years.&nbsp; Currently available data on paediatric patients are described in Section 5.1but no recommendation on a posology can be made.</p><p><u>Elderly (&gt;65years)</u></p><p>There is a limited amount of experience with patients 65 years of age or over receiving paricalcitol in the phase III studies.&nbsp; In these studies, no overall differences in efficacy or safety were observed between patients 65 years or older and younger patients.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Zemplar solution for injection is administered via haemodialysis access.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Vitamin D toxicity
Hypercalcemia


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br />Over suppression of parathyroid hormone may result in elevations of serum calcium levels and may lead to metabolic bone disease. Patient monitoring and individualized dose titration is required to reach appropriate physiological endpoints.</p><p>If clinically significant hypercalcemia develops, and the patient is receiving a calcium-based phosphate binder, the dose of the calcium-based phosphate binder should be reduced or interrupted.&nbsp;</p><p>Chronic hypercalcaemia may be associated with generalized vascular calcification and other soft-tissue calcification.</p><p>Phosphate or vitamin D-related medicinal products should not be taken concomitantly with paricalcitol due to an increased risk of hypercalcaemia and Ca x P product elevation (see Section 4.5).</p><p>Digitalis toxicity is potentiated by hypercalcemia of any cause, so caution should be applied when digitalis is prescribed concomitantly with paricalcitol (see section 4.5).&nbsp;</p><p>Caution should be exercised if co-administering paricalcitol with ketoconazole (see section 4.5).</p><p>This medicinal product contains 20% v/v of ethanol (alcohol). Each dose may contain up to 1.3g ethanol. &nbsp;Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high risk groups such as patients with liver disease or epilepsy.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with paricalcitol injection.&nbsp; However, an interaction study between Ketoconzole and paricalcitol has been performed with the capsule formulation.</p><p>Phosphate or vitamin D-related medicinal products should not be taken concomitantly with paricalcitol, due to an increased risk of hypercalcaemia and Ca x P product elevation (see Section 4.4)</p><p>High doses of calcium-containing preparations or thiazide diuretics may increase the risk of hypercalcaemia.</p><p>Aluminium-containing preparations (e.g., antacids, phosphate-binders) should not be administered chronically with Vitamin D medicinal products, as increased blood levels of aluminum and aluminum bone toxicity may occur.</p><p>Magnesium-containing preparations (e.g. antacids) should not be taken concomitantly with vitamin D preparations, because hypermagnesemia may occur.</p><p>Ketoconazole is known to be a non-specific inhibitor of several cytochrome P450 enzymes.&nbsp; The available in vivo and in vitro data suggest that ketoconazole may interact with enzymes that are responsible for the metabolism of paricalcitol and other vitamin D analogs.&nbsp; Caution should be taken while dosing paricalcitol with ketoconazole (see Section 4.4). The effect of multiple doses of ketaconazole administered as 200 mg, twice daily (BID) for 5 days on the pharmacokinetics of paricalcitol capsule has been studied in healthy subjects. The Cmax of paricalcitol was minimally affected, but AUC0-&infin; approximately doubled in the presence of ketoconazole. The mean half-life of paricalcitol was 17.0 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone. The results of this study indicate that following oral administration of paricalcitol the maximum amplification of the paricalcitol AUC &infin; from a drug interaction with ketoconazole is not likely to be greater than about two-fold.</p><p><strong>&nbsp;</strong></p><p>Digitalis toxicity is potentiated by hypercalcemia of any cause, so caution should be applied when digitalis is prescribed concomitantly with paricalcitol (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy:</u></p><p>There are no adequate data from the use of paricalcitol in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.&nbsp; Zemplar should not be used in pregnancy unless clearly necessary.</p><p>&nbsp;</p><p><u>Breast-feeding:</u></p><p>Animal studies have shown excretion of paricalcitol or its metabolites in breast milk, in small amounts.&nbsp; A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with paricalcitol should be made taking into account the benefit of breast-feeding to the child and the benefit of paricalcitol therapy to the woman.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paricalcitol may have minor influence on the ability to drive and use machines. Dizziness may occur following administration of paricalcitol (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 600 patients were treated with Zemplar in Phase II/III/IV clinical trials. Overall, 6% of the Zemplar treated patients reported adverse reactions.</p><p>&nbsp;</p><p>The most common adverse reaction associated with Zemplar therapy was hypercalcaemia, occurring in&nbsp;&nbsp; 4.7% of patients. Hypercalcaemia is dependent on the level of PTH oversuppression and can be minimised by proper dose titration.&nbsp;</p><p>&nbsp;</p><p>Adverse events at least possibly related to paricalcitol, both clinical and laboratory are displayed by MedDRA System Organ Class, Preferred<strong><em><u> </u></em></strong>Term and frequency<strong><em><u>.</u></em></strong> The following frequency groupings<strong><em><u> </u></em></strong>are used:&nbsp; Very common ( &ge; 1/10); common (&ge;<u> </u>1/100, &lt;1/10); uncommon (&ge; 1/1000, &lt;1/100); rare (&ge; 1/10,000, &lt;1/1000); very rare (&lt;1/10000),<em> </em>not known (can not be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:971px"><tbody><tr><td style="vertical-align:top; width:286px"><p><em>System Organ Class</em></p></td><td style="vertical-align:top; width:555px"><p>Preferred Term</p></td><td style="vertical-align:top; width:125px"><p>Frequency</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Investigations</p></td><td style="vertical-align:top; width:555px"><p>Bleeding time prolonged, aspartate aminotransferase increased, laboratory test abnormal, weight decreased</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:555px"><p>Cardiac arrest, arrhythmia, atrial flutter</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:555px"><p>Anaemia, leukopenia, lymphadenopathy</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:286px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:555px"><p>Headache, dysgeusia</p></td><td style="vertical-align:top; width:125px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Coma, cerebrovascular accident, transient ischemic attach, syncope, myoclonus, hypoaesthesia, paraesthesia, dizziness</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Eye disorders</p></td><td style="vertical-align:top; width:555px"><p>Glaucoma, conjunctivitis</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:555px"><p>Ear disorder</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:555px"><p>Pulmonary oedema, asthma, dyspnoea, epistaxis, cough</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:286px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:555px"><p>Rectal haemhorrhage, colitis, diarrhoea, gastritis, dyspepsia, dysphagia, abdominal pain, constipation, nausea, vomiting, dry mouth, gastrointestinal disorder</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Gastrointestinal haemorrhage</p></td><td style="vertical-align:top; width:125px"><p>unknown</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:286px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:555px"><p>Pruritus</p></td><td style="vertical-align:top; width:125px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Bullous dermatitis, alopecia, hirsutism,&nbsp; rash, hyperhidrosis</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:555px"><p>Arthralgia, joint stiffness, back pain, muscle twitching, myalgia</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:286px"><p>Endocrine Disorders</p></td><td style="vertical-align:top; width:555px"><p>Hypoparathyrodism</p></td><td style="vertical-align:top; width:125px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Hyperparathyrodism</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:286px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:555px"><p>Hypercalcaemia, Hyperphosphataemia</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>Common</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Hyperkalaemia, hypocalcemia, anorexia</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:555px"><p>Sepsis, pneumonia, infection pharyngitis, vaginal infection, influenza</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top; width:555px"><p>Breast cancer</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:555px"><p>Hypertension, hypotension</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:555px"><p>Gait disturbance, oedema, peripheral oedema, pain, injection site pain, pyrexia, chest pain, condition aggravated, asthenia, malaise, thirst&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:286px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:555px"><p>Hypersensitivity</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:555px"><p>Laryngeal oedema, angioedema, uritcaria</p></td><td style="vertical-align:top; width:125px"><p>Not Known</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:555px"><p>Breast pain, erectile dysfunction</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:286px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:555px"><p>Confusional state, delirium, depersonalization, agitation, insomnia, nervousness</p></td><td style="vertical-align:top; width:125px"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>● Fax: +966-11-205-7662</p><p>● Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>● Toll free phone: 8002490000</p><p>● E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp; Website: http://www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>Other GCC States:</p><p>-Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.</p><p>&nbsp;</p><p>Overdosage of paricalcitol may lead to hypercalcemia hypercalciuria, hyperphosphatemia, and over suppression of PTH (see section 4.4).</p><p>&nbsp;</p><p>In the event of an overdose, signs and symptoms of hypercalcemia (serum calcium levels) should be monitored and reported to a physician.&nbsp; Treatment should be initiated as appropriate.</p><p>&nbsp;</p><p>Paricalcitol is not significantly removed by dialysis. Treatment of patients with clinically significant hypercalcaemia consists of immediate dose reduction or interruption of paricalcitol therapy and includes a low calcium diet, withdrawal of calcium supplements, patient mobilisation, attention to fluid and electrolyte imbalances, assessment of electrocardiographic abnormalities (critical in patients receiving digitalis), and haemodialysis or peritoneal dialysis against a calcium-free dialysate, as warranted.</p><p>&nbsp;</p><p>When serum calcium levels have returned to within normal limits, paricalcitol may be reinitiated at a lower dose. If persistent and markedly elevated serum calcium levels occur, there are a variety of therapeutic alternatives that may be considered. These include the use of drugs such as phosphates and corticosteroids as well as measures to induce diuresis.</p><p>&nbsp;</p><p>Zemplar solution for injection contains 30% v/v of propylene glycol as an excipient. Isolated cases of Central Nervous System depression, haemolysis and lactic acidosis have been reported as toxic effect associated with propyleneglycol administration at high doses. Although they are not expected to be found with Zemplar administration as propyleneglycol is eliminated during the dialysis process, the risk of toxic effect in overdosing situations has to be taken into account.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Anti-parathyroid agents , ATC code: H05BX02</p><p>&nbsp;</p><p><u>Mechanism of action</u>:&nbsp;</p><p>Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring Unlike calcitriol, paricalcitol is a selective vitamin D receptor (VDR) activator.&nbsp; Paricalcitol selectively upregulates the VDR in the parathyroid glands without increasing VDR in the intestine and is less active on bone resorption. Paricalcitol also upregulates the calcium sensing receptor (CaSR) in the parathyroid glands. As a result, paricalcitol reduces parathyroid hormone (PTH) levels by inhibiting parathyroid proliferation and decreasing PTH synthesis and secretion, with minimal impact on calcium and phosphorus levels, and can act directly on bone cells to maintain bone volume and improve mineralization surfaces. Correcting abnormal PTH levels, with normalization of calcium and phosphorus homeostasis, may prevent or treat the metabolic bone disease associated with chronic kidney disease.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;The safety and effectiveness of Zemplar were examined in a 12-week randomised, double-blind, placebo-controlled study of 29 pediatric patients, aged 5-19 years, with end-stage renal disease on hemodialysis. The six youngest Zemplar-treated patients in the study were 5 - 12 years old. The initial dose of Zemplar was 0.04 microgram/kg 3 times per week, based on baseline iPTH level of less than 500 pg/mL, or 0.08 microgram<strong><em><u>/</u></em></strong>kg 3 times a week based on baseline iPTH level of &ge; 500 pg/mL, respectively. The dose of Zemplar was adjusted in 0.04 microgram/kg increments based on the levels of serum iPTH, calcium, and Ca x P. 67% of the Zemplar-treated patients and 14% placebo-treated patients completed the trial. 60% of the subjects in the Zemplar group had 2 consecutive 30% decreases from baseline iPTH compared with 21% patients in the placebo group. 71% of the placebo patients were discontinued due to excessive elevations in iPTH levels. No subjects in either the Zemplar group or placebo group developed hypercalcemia. No data are available for patients under the age of 5.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Distribution</em></p><p>The pharmacokinetics of paricalcitol have been studied in patients with chronic renal failure (CRF) requiring haemodialysis.&nbsp; Paricalcitol is administered as an intravenous bolus injection.&nbsp; Within two hours after administering doses ranging from 0.04 to 0.24 microgram/kg, concentrations of paricalcitol decreased rapidly; thereafter, concentrations of paricalcitol declined log-linearly with a mean half-life of about 15 hours.&nbsp; No accumulation of paricalcitol was observed with multiple dosing. <em>In vitro</em> plasma protein binding of paricalcitol was extensive (&gt;99.9%) and nonsaturable over the concentration range of 1 to 100 ng/mL.</p><p>&nbsp;</p><p><em>Biotransformation</em></p><p>Several unknown metabolites were detected in both the urine and faeces, with no detectable paricalcitol in the urine.&nbsp; These metabolites have not been characterised and have not been identified.&nbsp; Together, these metabolites contributed 51% of the urinary radioactivity and 59% of the faecal radioactivity.&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:528px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0" style="width:528px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Paricalcitol Pharmacokinetic Characteristics in CRF Patients (0.24 </strong><strong>m</strong><strong>g/kg dose)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Values (Mean </strong><strong>&plusmn;</strong><strong> SD)</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> ( 5 minutes after bolus)</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1850&plusmn;664 (pg/mL)</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>o-</sub><sub>&yen;</sub></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>27382 &plusmn; 8230 (pg&middot;hr/mL)</p></td></tr><tr><td style="vertical-align:top"><p>CL</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0.72 &plusmn; 0.24 (L/hr)</p></td></tr><tr><td style="vertical-align:top"><p>V<sub>ss</sub></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6 &plusmn; 2 (L)</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><p><em>Elimination </em></p><p>In healthy subjects, a study was conducted with a single 0.16 microgram/kg intravenous bolus dose of <sup>3</sup>H-paricalcitol (n=4), plasma radioactivity was attributed to parent substance.&nbsp; Paricalcitol was eliminated primarily by hepatobiliary excretion, as 74% of the radioactive dose was recovered in faeces and only 16% was found in urine.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><em>Gender, Race and Age</em>: No age or gender related pharmacokinetic differences have been observed in adult patients studied.&nbsp; Pharmacokinetic differences due to race have not been identified.</p><p><em>Hepatic impairment</em>:<em> </em>Unbound concentrations of paricalcitol in patients with mild to moderate hepatic&nbsp; impairment is similar to healthy subjects and dose adjustment is not necessary in this patient population. There is no experience in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Salient findings in the repeat dose toxicology studies in rodents and dogs were generally attributed to paricalcitol&rsquo;s calcaemic activity. Effects not clearly related to hypercalcaemia included decreased white blood cell counts and thymic atrophy in dogs, and altered APTT values (increased in dogs, decreased in rats).&nbsp;&nbsp; WBC changes were not observed in clinical trials of paricalcitol.</p><p>Paricalcitol did not affect fertility in rats and there was no evidence of teratogenic activity in rats or rabbits. High doses of other vitamin D preparations applied during pregnancy in animals lead to teratogenesis. Paricalcitol was shown to affect fetal viability, as well as to promote a significant increase of peri-natal and post-natal mortality of newborn rats, when administered at maternally toxic doses.</p><p>&nbsp;</p><p>Paricalcitol did not exhibit genotoxic potential in a set of <em>in-vitro </em>and <em>in-vivo </em>genotoxicity assays</p><p>Carcinogenicity studies in rodents did not indicate any special risks for human use.</p><p>Doses administered and/or systemic exposures to paricalcitol were slightly higher than therapeutic doses/systemic exposures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethanol (20&nbsp;% v/v)</p><p>Propylene glycol</p><p>Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatability studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p><p>Propylene glycol interacts with heparin and neutralises its effect. Zemplar solution for injection contains propylene glycol as an excipient and should be administered through a different injection port than heparin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

After opening, use immediately



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30˚C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each Type 1 glass ampoule contains 1mL or 2mL of solution for injection.</p><p>Each Type 1 glass vial contains 1mL or 2mL of solution for injection.</p><p>&nbsp;</p><p>The presentations of Zemplar are:</p><p>Pack containing 5 ampoules of 1mL of solution for injection</p><p>Pack containing 5 ampoules of 2mL of solution for injection</p><p>Pack containing 5 vials of 1mL of solution for injection</p><p>Pack containing 5 vials of 2mL of solution for injection</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration. The solution is clear and colourless.</p><p>For single use only.</p><p>Any unused medicinal product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Ltd.,
AbbVie House
Maidenhead, Berkshire
SL6 4UB
United Kingom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April  2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>